S
Stockadora

Recent Annual Reports

Browse the latest SEC filings with AI-powered analysis. Get insights into corporate performance, financial trends, and business developments.

📊 4770 Reports
🤖 AI Analyzed
Recent
📄 Page 117 of 398
PRECIGEN, INC.
10-K March 25, 2026

Key Highlights

  • Advancing PRGN-2012 for recurrent respiratory papillomatosis with FDA Fast Track...
  • Strategic pivot from research-focused operations to commercialization of the Ult...
  • Divestiture of Trans Ova Genetics for $15 million to prioritize core oncology pi...
Read Analysis
🤖 AI Generated
KIORA PHARMACEUTICALS INC
10-K March 25, 2026

Key Highlights

  • KIO-301 received Orphan Drug Designation, providing 7 years of market exclusivit...
  • Strategic partnership with Thea Open Innovation (TOI) provides non-dilutive fund...
  • Advancing two clinical-stage assets: ABACUS-2 (KIO-301) for vision restoration a...
Read Analysis
🤖 AI Generated
ProMIS Neurosciences Inc.
10-K March 25, 2026

Key Highlights

  • Advancing PMN310, a precision antibody treatment for Alzheimer’s disease current...
  • Potential for high-value partnership or buyout if clinical results demonstrate s...
  • Strong focus on neurodegenerative pipeline including PMN442 and PMN267 for ALS a...
Read Analysis
🤖 AI Generated
Oak Valley Bancorp
10-K March 25, 2026

Key Highlights

  • Stable asset growth of 6.4% reaching $2.02 billion.
  • Conservative lending strategy with a 44.9% average loan-to-value ratio.
  • Consistent dividend payments supported by a healthy 12.5% capital ratio.
Read Analysis
🤖 AI Generated
TPI COMPOSITES, INC
10-K March 25, 2026

Key Highlights

  • Company is currently in Chapter 11 bankruptcy liquidation
  • Asset sales to Vestas and ECP totaling $44 million
  • Delisted from Nasdaq and now trading on OTC Pink as TPICQ
Read Analysis
🤖 AI Generated
Everpure, Inc.
10-K March 25, 2026

Key Highlights

  • Subscription revenue grew 26% to $1.17 billion, signaling a successful transitio...
  • Everpure’s technology enables up to 85% reduction in data center power usage, a ...
  • Strong balance sheet with $1.2 billion in cash and investments supports R&D and ...
Read Analysis
🤖 AI Generated
ATOSSA THERAPEUTICS, INC.
10-K March 25, 2026

Key Highlights

  • Lead drug (Z)-endoxifen showed a 72% reduction in tumor size in the I-SPY 2 tria...
  • Karisma Phase 2 study demonstrated up to 23.5% reduction in breast density.
  • Cash position of $23.4 million provides runway into 2027.
Read Analysis
🤖 AI Generated
Paysign, Inc.
10-K March 25, 2026

Key Highlights

  • Revenue grew 40.5% to $62.8 million, driven by a 167.8% surge in the pharmaceuti...
  • Profitability nearly doubled year-over-year, rising from $3.8 million to $7.55 m...
  • Strong balance sheet with $18.4 million in cash and zero long-term debt to fund ...
Read Analysis
🤖 AI Generated
Nexalin Technology, Inc.
10-K March 25, 2026

Key Highlights

  • Innovative 'razor-and-blade' business model using proprietary smart electrodes f...
  • Development of advanced Gen-2 and Gen-3 neurostimulation devices for mental heal...
  • Expansion into telehealth models to bypass traditional clinical stigma.
Read Analysis
🤖 AI Generated
TELA Bio, Inc.
10-K March 25, 2026

Key Highlights

  • Innovative 'Goldilocks' product combines natural tissue with polymer for superio...
  • Strong revenue growth of 16% YoY reaching $80.3 million.
  • High gross profit margin of 68% driven by manufacturing efficiencies.
Read Analysis
🤖 AI Generated
Gulf Coast Ultra Deep Royalty Trust
10-K March 25, 2026

Key Highlights

  • Highlander-2 well completed in early 2026 to potentially restore revenue
  • Passive royalty interest in 3.6% of deep-water offshore Louisiana assets
  • Trust structure allows for potential share buyout at $0.25 if price remains low
Read Analysis
🤖 AI Generated

Stay Informed with AI Analysis

Get comprehensive insights from annual reports with our AI-powered analysis. Track corporate performance, financial trends, and strategic developments.

Back to Homepage